Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice.

[1]  B. Rollins,et al.  Monocyte chemoattractant protein-1. , 1999, Chemical immunology.

[2]  M. Baggiolini.  Chemokines and leukocyte traffic , 1998, Nature.

[3]  B. Rollins,et al.  Abnormalities in Monocyte Recruitment and Cytokine Expression in Monocyte Chemoattractant Protein 1–deficient Mice , 1998, The Journal of experimental medicine.

[4]  M. Jaye,et al.  Monocyte chemoattractant protein‐2 is a potent agonist of CCR2B , 1997, Journal of leukocyte biology.

[5]  R. Bravo,et al.  Defects in Macrophage Recruitment and Host Defense in Mice Lacking the CCR2 Chemokine Receptor , 1997, The Journal of experimental medicine.

[6]  Robert V Farese,et al.  Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. , 1997, The Journal of clinical investigation.

[7]  K. Ley,et al.  Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. Rollins,et al.  Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: abrogation by a second transgene expressing systemic MCP-1. , 1997, Journal of immunology.

[9]  R. Nibbs,et al.  Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5. , 1997, The Journal of biological chemistry.

[10]  P. Libby,et al.  Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. , 1997, The American journal of pathology.

[11]  Hao Li,et al.  Production of the novel C-C chemokine MCP-4 by airway cells and comparison of its biological activity to other C-C chemokines. , 1997, The Journal of clinical investigation.

[12]  A. Luster,et al.  Murine Monocyte Chemoattractant Protein (MCP)-5: A Novel CC Chemokine That Is a Structural and Functional Homologue of Human MCP-1 , 1997, The Journal of experimental medicine.

[13]  L. Williams,et al.  Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation. , 1997, Journal of immunology.

[14]  Q. Hamid,et al.  Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. , 1996, Journal of immunology.

[15]  S. Kunkel,et al.  Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation: relationship to local inflammation, Th cell expression, and IL-12 production. , 1996, Journal of immunology.

[16]  T. Kurihara,et al.  Cloning and Functional Expression of mCCR2, a Murine Receptor for the C-C Chemokines JE and FIC (*) , 1996, Journal of Biological Chemistry.

[17]  J. Breslow.  Mouse Models of Atherosclerosis , 1996, Science.

[18]  I. Goldberg.  Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. , 1996, Journal of lipid research.

[19]  J. Van Damme,et al.  Monocyte Chemoattractant Protein-3 Is a Functional Ligand for CC Chemokine Receptors 1 and 2B (*) , 1995, The Journal of Biological Chemistry.

[20]  R. Bravo,et al.  Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. , 1995, Journal of immunology.

[21]  E M Rubin,et al.  Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. , 1995, Journal of lipid research.

[22]  Koichiro Nakamura,et al.  Keratinocyte-derived monocyte chemoattractant protein 1 (MCP-1): analysis in a transgenic model demonstrates MCP-1 can recruit dendritic and Langerhans cells to skin. , 1995, The Journal of investigative dermatology.

[23]  Michael Ginsberg,et al.  Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Proost,et al.  Monocyte chemoattractant protein-3, but not monocyte chemoattractant protein-2, is a functional ligand of the human monocyte chemoattractant protein-1 receptor. , 1995, Journal of immunology.

[25]  R. Ross,et al.  Cell biology of atherosclerosis. , 1995, Annual review of physiology.

[26]  M. D. de Bruijn,et al.  Markers of mouse macrophage development detected by monoclonal antibodies. , 1994, Journal of immunological methods.

[27]  S Chien,et al.  Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D K Burns,et al.  Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. , 1994, The Journal of clinical investigation.

[29]  A. Mantovani,et al.  Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1. , 1994, Journal of immunology.

[30]  S. Coughlin,et al.  Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Ross,et al.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[32]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[33]  P. Libby,et al.  Cytokines and growth factors in atherogenesis. , 1992, Archives of pathology & laboratory medicine.

[34]  D Schwartz,et al.  A Cascade Model for Restenosis: A Special Case of Atherosclerosis Progression , 1992, Circulation.

[35]  A. J. Valente,et al.  Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Montalescot,et al.  Myocardial Viability in Patients With Q Wave Myocardial Infarction and No Residual Ischemia , 1992, Circulation.

[37]  M. Ferguson,et al.  Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. , 1992, The Journal of clinical investigation.

[38]  B. Rollins,et al.  JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. , 1992, Circulation research.

[39]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[40]  D. Steinberg,et al.  Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Coughlin,et al.  Monocyte chemoattractant protein-1 in human atheromatous plaques. , 1991, The Journal of clinical investigation.

[42]  D. Steinberg,et al.  Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. J. Valente,et al.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Leonard,et al.  Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. , 1990, The American journal of pathology.

[45]  M. Territo,et al.  Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. , 1990, The Journal of clinical investigation.

[46]  R. Strieter,et al.  Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells. , 1989, Biochemical and biophysical research communications.

[47]  M. Rep,et al.  Macrophages in T and B Cell Compartments and Other Tissue Macrophages Recognized by Monoclonal Antibody MOMA‐2 , 1987, Scandinavian journal of immunology.

[48]  R. Williams,et al.  Quantitative assessment of atherosclerotic lesions in mice. , 1987, Atherosclerosis.

[49]  A. Gown,et al.  Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. , 1986, The American journal of pathology.

[50]  G. Bondjers,et al.  Regional Accumulations of T Cells, Macrophages, and Smooth Muscle Cells in the Human Atherosclerotic Plaque , 1986, Arteriosclerosis.

[51]  M. Haine,et al.  Van Damme A. , 1986 .

[52]  H. Waldmann,et al.  Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies , 1985, The Journal of pathology.

[53]  Gerrity Rg.  The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. , 1981 .